Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04052048 · ClinicalTrials.gov registry record
Active Surveillance SNEP Assay Registry Trial for Prostate Cancer
A clinical trial of Prostate Cancer Aggressiveness, sponsored by Immunis.AI.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT04052048 is a study of Prostate Cancer Aggressiveness that is actively recruiting participants, run by Immunis.AI. The registered enrollment target is 2,000 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04052048, a study of Prostate Cancer Aggressiveness, is actively recruiting participants, sponsored by Immunis.AI.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
A multi-center, prospective active surveillance registry trial assessing the performance of a non-invasive blood test for indolent prostate cancer disease management.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Subtraction Normalized Expression of Phagocytes Blood Test
Study Locations (1)
Michigan
- Comprehensive Urology - Royal Oak
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2019-09-09 |
| Est. Completion | 2029-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04052048
The ClinicalTrials.gov registry entry for NCT04052048 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immunis.AI, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer Aggressiveness appearing as the primary indexed condition, and to 1 intervention - of which Subtraction Normalized Expression of Phagocytes Blood Test is the first listed.
NCT04052048 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT04052048 about?
NCT04052048 is a clinical study titled "Active Surveillance SNEP Assay Registry Trial for Prostate Cancer". A multi-center, prospective active surveillance registry trial assessing the performance of a non-invasive blood test for indolent prostate cancer disease management.
What is the current status of trial NCT04052048?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2019-09-09. Estimated completion is 2029-09-30.
What conditions does trial NCT04052048 study?
This clinical trial studies the following conditions: Prostate Cancer Aggressiveness.
What interventions are being tested in trial NCT04052048?
The interventions under investigation include: Subtraction Normalized Expression of Phagocytes Blood Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04052048?
This trial is sponsored by Immunis.AI, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04052048 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer Aggressiveness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.